- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
MEA
Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
Asia Pacific
Future Market Insights Global & Consulting Pvt. Ltd.
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Enzyme Replacement Therapy Market

Enzyme Replacement Therapy Market by Therapeutic Condition, Route of Administration, Distribution Channel & Region - Forecast 2022 - 2028

Market Insights on Enzyme Replacement Therapy covering sales outlook, demand forecast and up-to-date key trends

Request Sample

Enzyme Replacement Therapy Market Outlook (2022-2028)

[305 Pages Report] The global enzyme replacement therapy market is expected to be worth US$ 9.3 Billion in 2022, with a CAGR of 6.7% to reach US$ 13.8 Billion by the end of 2028. Enzyme replacement therapy (ERT) revenue accounts for approximately 63% of the global hormone replacement market. The increased incidence of rare diseases has majorly contributed to the use of enzyme replacement therapies, and medical research is expected to accelerate this progress further. According to Future Market Insights, the market of enzyme replacement therapy is attributed to the below-mentioned reasons:

  • The increase in BPS values is connected to increased research into rare disease avenues as well as the innovation of orphan drug delivery systems.
  • The recent increase in the occurrence of rare and ultra-rare diseases.
  • An increase in the number of rare diseases that require novel treatment approaches, an increase in the availability of enzyme replacement therapies, increased awareness, and less stringent regulations for rare disease treatment.
  • Expanding medical research and public awareness about enzyme replacement therapies.

The COVID-19 pandemic entirely changed the way the world viewed healthcare, resulting in significant developments and shifts in the medical industry. Coronavirus diseases spread rapidly throughout the world, reinventing healthcare systems worldwide. Countries went into complete lockdown, and many essential activities and operations ceased abruptly, causing markets to halt.

The ERT industry was also affected by the abrupt closure of supply and demand chains around the world. Due to global lockdown restrictions, the enzyme replacement therapy market also suffered a detrimental effect on research and development.

Enzyme Replacement Therapy Market Size (2022)

US$ 9.3 Bn

Revenue Estimation (2028)

US$ 13.8 Bn

Global Market Growth Rate (2022-2028)

6.7% CAGR

North America Market Share

28.6%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Market Growth to Ride on Elevating Demand in North America and Europe

North America's enzyme replacement therapy industry offers a dominant market share of 28.6% in 2022, leading the global market landscape. This region is anticipated to be one of the greatest lucrative businesses for enzyme replacement therapy, with rising healthcare spending driving ERT demand. The United States is projected to lead the industry of enzyme replacement therapy in North America.

Western Europe's enzyme replacement therapy market is following closely. The region has witnessed a substantial increase in rare disease cases in recent years, which has induced the growth of enzyme replacement therapy demand. Both Germany and the Kingdom, for example, have a higher prevalence of Fabry's disease and other chronic illnesses, which drives demand for enzyme replacement therapy. The sheer volume of MPS and SCID patients is one of the factors driving market growth in the European region.

Enzyme Replacement Therapy Market

Key players to bolster the growth by upgrading Products and Technology

The market has a large number of both global and local players. The vast bulk of these market participants is well-known for their portfolio of inherited metabolic diseases, making treatment simple and effective.

Shire Plc, Sanofi S.A., AbbVie, and Allergan plc, for example, have a strong presence worldwide in terms of a supply chain network and operating facilities. Key players are primarily concerned with developing and marketing drugs for rare and genetic diseases. For example, Shire, plc has over 40 products sold globally that are solely focused on rare and orphan diseases. The manufacturer is also committed to raising awareness about these diseases and, as a result, is constantly launching new campaigns to increase awareness.

In addition, major players are pursuing mergers, acquisitions, and strategic alliances, which are predicted to propel the enzyme replacement therapy market. The majority of the firms are concentrating on the creation of new items. Diverse companies are also entailed in the licensing and distribution of drugs in order to better assist patients.

Revenue from enzyme replacement therapy (ERT) accounts for around 63% share of the global hormone replacement market. Increasing prevalence of rare diseases has majorly led to the deployment of enzyme replacement therapies, and medical research is expected to further advance these developments.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

6.52%

H1, 2022 Projected

6.66%

H1, 2022 Outlook

6.56%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 10 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(+) 04 ↑

The comparative analysis and market growth rate of global enzyme replacement therapy market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, and, a surge in BPS values is expected in H1-2022 over H1- 2021 duration with only 04 Basis Point Share (BPS).

The global enzyme replacement therapy market is subject to external funding and grants for development of products, and reimbursement guidelines for specified therapies.

The key developments in the market include development of treatments for rare diseases, encapsulation of enzymes to enhance stability, and growing studies to utilize virosomes for enzyme delivery. The market is highly influenced by the high treatment costs, prevalence of disease, and the anatomical side effects associated with the therapy.

The market decline observed through the drop in the BPS values is addressed by the short in-vivo half-life of the enzymes, lack of targeted action and tissue specificity, and patient immune system reaction against the enzyme.

Conversely, the spike in BPS values is associated with the growing research within rare disease avenues as well as the development of orphan drug delivery systems. Moreover, the efficacy of enzyme replacement therapies have further promoted their adoption, thus assisting with the growing market values.

Enzyme Replacement Therapy Demand Analysis (2013 to 2021) Vs Market Predictions (2022 to 2028)

The enzyme replacement therapy market is expected to flourish over the coming years as instances of rare and unknown diseases increase on a global scale. There has been a surge in the emergence of rare and ultra-rare diseases over the past few years, and this trend is not expected to slow down anytime soon. The need for orphan disease management and orphan drugs has seen a substantial increase as rare diseases have become more frequent.

Enzyme replacement therapy demand increased at a CAGR of 6.4% from 2013 to 2021 and ended up with a value of US$ 8.8 Bn in 2021. Increasing instances of rare diseases that require unique treatment approaches, rising availability of enzyme replacement therapies, increasing awareness, and less tough regulations for rare disease treatment are primarily driving demand for ERT.

Increasing medical research and rising awareness about enzyme replacement therapies are expected to be common factors propelling ERT market growth across the world.

All in all, the global enzyme replacement therapy market is predicted to progress at a CAGR of 6.7% from 2022 to 2028.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Which Region is Most Lucrative for Enzyme Replacement Therapy Providers?

This enzyme replacement therapy industry survey by FMI covers market statistics on a global scale, and especially gives metrics specific to regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).

Leading the global market landscape, the North America enzyme replacement therapy market holds a dominant market share of 28.6% in 2022.

This region is expected to be one of the most lucrative markets for enzyme replacement treatment, and ERT demand is expected to be driven by rising healthcare expenditure in the region. The U.S. is expected to lead the North American enzyme replacement therapy industry.

Following closely is the Western Europe enzyme replacement therapy market. The region, over the past few years, has experienced tremendous increase in rare disease instances, and this has influentially shaped the enzyme replacement therapy demand growth.

For instance, Germany and the U.K. have a high incidence of Fabry’s disease and other rare diseases as well that drives demand for enzyme replacement therapy.

East Asia, South Asia, and the Pacific regions are expected to exhibit lucrative opportunities for enzyme replacement therapy providers over the coming years.

Rising disposable income, developing healthcare systems, increasing awareness are major factors influencing the enzyme replacement therapy market potential in these regions. Japan, India, and China are expected to be leading nations in these regions.

Demand for enzyme replacement treatment in MEA is anticipated to rise at a steady pace over the forecast period; the region currently holds around 3% of the global market share.

Country-wise Analysis

What’s Driving Demand for Enzyme Replacement Therapy in Japan?

Japan is one of the most technologically advanced nations in the world and has an advanced healthcare system to accommodate the nation’s healthcare needs in the most efficient manner possible. Advancements in the medical research field in Japan are expected to propel enzyme replacement therapy market growth majorly in the nation.

Apart from this, growing geriatric population and increasing incidence of rare diseases are also anticipated to complement enzyme replacement therapy demand over the forecast period. Japan accounts for nearly 23% share of the global enzyme replacement therapy market in terms of volume, at present.

How Can Enzyme Replacement Therapy Providers Maximize their Revenue Potential in the U.S.?

The U.S. is one of the most important healthcare markets of the world and also one of the most advanced ones. Enzyme replacement therapy solution providers can target this nation to take advantage of the advanced and developed healthcare infrastructure that provides a lucrative setting for major medical research breakthroughs and promotes novel drug development practices.

Adoption of advanced and innovative technologies, presence of leading ERT providers, and increasing investments in medical research & development are some other factors driving demand for enzyme replacement therapy in the U.S.

Leading as well as new enzyme replacement therapy providers can target this market to make their mark in the global industry landscape and further establish themselves.

Category-wise Analysis

Which Route of Administration for ERT is Expected to Hold Highest Share?

Administration of enzyme replacement therapy is majorly through oral or injectable means, and of these two, injectable ERT is expected to lead the global market in terms of share over the forecast period. Increase in demand for injectable ERT drugs is expected to majorly drive the injectable segment to domination over the coming years.

Injectable ERT is predicted to account for more than 80% of the global enzyme replacement therapy market while accounting for major revenue generation opportunities.

COVID-19 Crisis Analysis

The COVID-19 pandemic completely changed the way the world approached healthcare and led to some major changes and advancements in the medical industry. Coronavirus infections spread rampantly throughout the world and revolutionized the healthcare systems across the world. Countries went into a complete lockdowns and many essential activities and operations stopped abruptly and halted markets.

The ERT industry was also disrupted due to the abrupt shutdown of supply and demand chains across the world. The enzyme replacement therapy market also saw a negative impact on the research and development aspect due to lockdown restrictions across the world.

But this has changed and is expected to change further in the post-pandemic era as the world returns to normalcy and research & development related to enzyme replacement therapy pick up pace.

Competitive Landscape

Enzyme replacement therapy providers are focusing on medical research & development to develop effective treatments for various rare diseases. Companies developing enzyme replacement therapies can target regions where instances of rare diseases are frequent and rising.

  • In August 2021, the U.S. Food and Drug Administration (FDA) approved the use of Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of Pompe disease. The approved drug would be used in the treatment of patients of one year of age or older with late-onset Pompe disease. It is an enzyme deficiency that leads to the accumulation of complex sugar called glycogen in skeletal and heart muscles, and is a rare disease.
  • In May 2021, Aceragen, a biopharmaceutical firm focused on transformational therapeutics, announced the acquisition of Enzyvant’s RVT-801 (now ACG-801). It is an investigational enzyme replacement therapy for ceramidase deficiency presenting itself as Farber disease for which no disease-specific therapy is present.

Enzyme Replacement Therapy Industry Report Scope

Attribute

Details

Forecast Period

2022-2028

Historical Data Available for

2013-2021

Market Analysis

US$ Mn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa (MEA)

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • Turkey
  • South Africa
  • and GCC Countries

Key Market Segments Covered

  • Therapeutic Condition
  • Route of Administration
  • Distribution Channel
  • Region

Key Companies Profiled

  • Sanofi S.A. (Genzyme Corporation)
  • Shire plc.
  • Pfizer Inc.
  • Alexion Pharmaceuticals Inc.
  • BioMarin Pharmaceutical Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Johnson & Johnson Services Inc.
  • Allergan plc.
  • Leadiant Biosciences Inc.

Pricing

Available upon Request

Key Segments of Enzyme Replacement Therapy Industry Survey

Enzyme Replacement Therapy Market by Therapeutic Condition:

  • Enzyme Replacement Therapy for Fabry Disease
  • Enzyme Replacement Therapy for Gaucher Disease
  • Enzyme Replacement Therapy for Mucopolysaccharidosis
    • MPS I
    • MPS II (Hunter Syndrome)
    • MPS IVA (Morquio Syndrome, Type A)
    • MPS VI (Maroteaux-Lamy Syndrome)
    • MPS VII (Sly Syndrome)
  • Enzyme Replacement Therapy for Pompe Disease
  • Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
  • Others

Enzyme Replacement Therapy Market by Route of Administration:

  • Oral Enzyme Replacement Therapy
  • Injectable Enzyme Replacement Therapy

Enzyme Replacement Therapy Market by Distribution Channel:

  • Hospital Pharmacies
  • Specialty Treatment Pharmacies
  • Retail Pharmacies

Enzyme Replacement Therapy Market by Region:

  • North America Enzyme Replacement Therapy Market
  • Latin America Enzyme Replacement Therapy Market
  • Europe Enzyme Replacement Therapy Market
  • East Asia Enzyme Replacement Therapy Market
  • South Asia & Pacific Enzyme Replacement Therapy Market
  • Middle East & Africa (MEA) Enzyme Replacement Therapy Market

Frequently Asked Questions

The enzyme replacement therapy market is expected to capture a CAGR of 6.7% through 2028.

The market's historical performance was positive, with a CAGR of 6.4% from 2013 to 2021.

North America, Europe, and Asia Pacific are the top 3 countries leading the market.

Injectable enzyme replacement therapy is the dominant product type in the enzyme replacement therapy market

Rising disposable income and increasing awareness are the factors expanding Asia Pacific’s market remarkably.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

3. Market View Point Analysis

    3.1. Macro-Economic Factors

    3.2. Market Dynamics

        3.2.1. Drivers

        3.2.2. Restraints

        3.2.3. Trends

    3.3. Opportunity Analysis

    3.4. Value Chain Analysis

4. Macroeconomic Assumptions

5. Global Economic Outlook

    5.1. Gross Domestic Product by Region & Country, 2006 – 2021

    5.2. Global Pharmaceutical Market Outlook

6. Key Inclusions

    6.1. Rare Disease Framework

    6.2. Orphan Drug Key Regulations, By Country

    6.3. Pipeline Assessment of Enzyme Replacement Therapy

7. North America Market Analysis 2013-2021 and Forecast 2022-2028

    7.1. Introduction

    7.2. Regional Market Trends

    7.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        7.3.1. U.S.

        7.3.2. Canada

    7.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    7.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        7.5.1. Fabry Disease

        7.5.2. Gaucher Disease

        7.5.3. Mucopolysaccharidosis

            7.5.3.1. MPS I

            7.5.3.2. MPS II (Hunter syndrome)

            7.5.3.3. MPS IVA (Morquio syndrome, type A)

            7.5.3.4. MPS VI (Maroteaux-Lamy syndrome)

            7.5.3.5. MPS VII (Sly syndrome)

        7.5.4. Pompe Disease

        7.5.5. Lysosomal acid lipase Deficiency

        7.5.6. Others

    7.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    7.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        7.7.1. Oral

        7.7.2. Injectable

    7.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    7.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        7.9.1. Hospital Pharmacies

        7.9.2. Specialty Treatment Pharmacies

        7.9.3. Retail Pharmacies

    7.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    7.11. Market Attractiveness Analysis

        7.11.1. By Country

        7.11.2. By Therapeutic Condition

        7.11.3. By Route of Administration

        7.11.4. By Distribution Channel

    7.12. Drivers and Restraints: Impact Analysis

    7.13. Key Market Participants – Intensity Mapping

8. Latin America Market Analysis 2013-2021 and Forecast 2022-2028

    8.1. Introduction

    8.2. Regional Market Trends

    8.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        8.3.1. Brazil

        8.3.2. Mexico

        8.3.3. Rest of Latin America

    8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    8.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        8.5.1. Fabry Disease

        8.5.2. Gaucher Disease

        8.5.3. Mucopolysaccharidosis

            8.5.3.1. MPS I

            8.5.3.2. MPS II (Hunter syndrome)

            8.5.3.3. MPS IVA (Morquio syndrome, type A)

            8.5.3.4. MPS VI (Maroteaux-Lamy syndrome)

            8.5.3.5. MPS VII (Sly syndrome)

        8.5.4. Pompe Disease

        8.5.5. Lysosomal acid lipase Deficiency

        8.5.6. Others

    8.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    8.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        8.7.1. Oral

        8.7.2. Injectable

    8.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    8.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        8.9.1. Hospital Pharmacies

        8.9.2. Specialty Treatment Pharmacies

        8.9.3. Retail Pharmacies

    8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    8.11. Market Attractiveness Analysis

        8.11.1. By Country

        8.11.2. By Therapeutic Condition

        8.11.3. By Route of Administration

        8.11.4. By Distribution Channel

    8.12. Drivers and Restraints: Impact Analysis

    8.13. Key Market Participants – Intensity Mapping

9. Western Europe Market Analysis 2013-2021 and Forecast 2022-2028

    9.1. Introduction

    9.2. Regional Market Trends

    9.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        9.3.1. Germany

        9.3.2. U.K

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Rest of Western Europe

    9.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    9.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        9.5.1. Fabry Disease

        9.5.2. Gaucher Disease

        9.5.3. Mucopolysaccharidosis

            9.5.3.1. MPS I

            9.5.3.2. MPS II (Hunter syndrome)

            9.5.3.3. MPS IVA (Morquio syndrome, type A)

            9.5.3.4. MPS VI (Maroteaux-Lamy syndrome)

            9.5.3.5. MPS VII (Sly syndrome)

        9.5.4. Pompe Disease

        9.5.5. Lysosomal acid lipase Deficiency

        9.5.6. Others

    9.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    9.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        9.7.1. Oral

        9.7.2. Injectable

    9.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    9.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        9.9.1. Hospital Pharmacies

        9.9.2. Specialty Treatment Pharmacies

        9.9.3. Retail Pharmacies

    9.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    9.11. Market Attractiveness Analysis

        9.11.1. By Country

        9.11.2. By Therapeutic Condition

        9.11.3. By Route of Administration

        9.11.4. By Distribution Channel

    9.12. Drivers and Restraints: Impact Analysis

    9.13. Key Market Participants – Intensity Mapping

10. Eastern Europe Market Analysis 2013-2021 and Forecast 2022-2028

    10.1. Introduction

    10.2. Regional Market Trends

    10.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        10.3.1. Russia

        10.3.2. Poland

        10.3.3. Rest of Eastern Europe

    10.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    10.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        10.5.1. Fabry Disease

        10.5.2. Gaucher Disease

        10.5.3. Mucopolysaccharidosis

            10.5.3.1. MPS I

            10.5.3.2. MPS II (Hunter syndrome)

            10.5.3.3. MPS IVA (Morquio syndrome, type A)

            10.5.3.4. MPS VI (Maroteaux-Lamy syndrome)

            10.5.3.5. MPS VII (Sly syndrome)

        10.5.4. Pompe Disease

        10.5.5. Lysosomal acid lipase Deficiency

        10.5.6. Others

    10.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    10.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        10.7.1. Oral

        10.7.2. Injectable

    10.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    10.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        10.9.1. Hospital Pharmacies

        10.9.2. Specialty Treatment Pharmacies

        10.9.3. Retail Pharmacies

    10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    10.11. Market Attractiveness Analysis

        10.11.1. By Country

        10.11.2. By Therapeutic Condition

        10.11.3. By Route of Administration

        10.11.4. By Distribution Channel

    10.12. Drivers and Restraints: Impact Analysis

    10.13. Key Market Participants – Intensity Mapping

11. Asia Pacific Excluding China & Japan Market Analysis 2013-2021 and Forecast 2022-2028

    11.1. Introduction

    11.2. Regional Market Trends

    11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        11.3.1. India

        11.3.2. Australia and New Zealand

        11.3.3. ASEAN

        11.3.4. Rest of APECJ

    11.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    11.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        11.5.1. Fabry Disease

        11.5.2. Gaucher Disease

        11.5.3. Mucopolysaccharidosis

            11.5.3.1. MPS I

            11.5.3.2. MPS II (Hunter syndrome)

            11.5.3.3. MPS IVA (Morquio syndrome, type A)

            11.5.3.4. MPS VI (Maroteaux-Lamy syndrome)

            11.5.3.5. MPS VII (Sly syndrome)

        11.5.4. Pompe Disease

        11.5.5. Lysosomal acid lipase Deficiency

        11.5.6. Others

    11.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    11.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        11.7.1. Oral

        11.7.2. Injectable

    11.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    11.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        11.9.1. Hospital Pharmacies

        11.9.2. Specialty Treatment Pharmacies

        11.9.3. Retail Pharmacies

    11.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    11.11. Market Attractiveness Analysis

        11.11.1. By Country

        11.11.2. By Therapeutic Condition

        11.11.3. By Route of Administration

        11.11.4. By Distribution Channel

    11.12. Drivers and Restraints: Impact Analysis

    11.13. Key Market Participants – Intensity Mapping

12. China Market Analysis 2013-2021 and Forecast 2022-2028

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        12.2.1. Fabry Disease

        12.2.2. Gaucher Disease

        12.2.3. Mucopolysaccharidosis

            12.2.3.1. MPS I

            12.2.3.2. MPS II (Hunter syndrome)

            12.2.3.3. MPS IVA (Morquio syndrome, type A)

            12.2.3.4. MPS VI (Maroteaux-Lamy syndrome)

            12.2.3.5. MPS VII (Sly syndrome)

        12.2.4. Pompe Disease

        12.2.5. Lysosomal acid lipase Deficiency

        12.2.6. Others

    12.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    12.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        12.4.1. Oral

        12.4.2. Injectable

    12.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    12.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        12.6.1. Hospital Pharmacies

        12.6.2. Specialty Treatment Pharmacies

        12.6.3. Retail Pharmacies

    12.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    12.8. Market Attractiveness Analysis

        12.8.1. By Therapeutic Condition

        12.8.2. By Route of Administration

        12.8.3. By Distribution Channel

    12.9. Drivers and Restraints: Impact Analysis

    12.10. Key Market Participants – Intensity Mapping

13. Japan Market Analysis 2013-2021 and Forecast 2022-2028

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        13.2.1. Fabry Disease

        13.2.2. Gaucher Disease

        13.2.3. Mucopolysaccharidosis

            13.2.3.1. MPS I

            13.2.3.2. MPS II (Hunter syndrome)

            13.2.3.3. MPS IVA (Morquio syndrome, type A)

            13.2.3.4. MPS VI (Maroteaux-Lamy syndrome)

            13.2.3.5. MPS VII (Sly syndrome)

        13.2.4. Pompe Disease

        13.2.5. Lysosomal acid lipase Deficiency

        13.2.6. Others

    13.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    13.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        13.4.1. Oral

        13.4.2. Injectable

    13.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    13.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        13.6.1. Hospital Pharmacies

        13.6.2. Specialty Treatment Pharmacies

        13.6.3. Retail Pharmacies

    13.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    13.8. Market Attractiveness Analysis

        13.8.1. By Therapeutic Condition

        13.8.2. By Route of Administration

        13.8.3. By Distribution Channel

    13.9. Drivers and Restraints: Impact Analysis

    13.10. Key Market Participants – Intensity Mapping

14. Middle East and Africa Market Analysis 2013-2021 and Forecast 2022-2028

    14.1. Introduction

    14.2. Regional Market Trends

    14.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

        14.3.1. GCC Countries

        14.3.2. South Africa

        14.3.3. Rest of Middle East and Africa

    14.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    14.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2021

        14.5.1. Fabry Disease

        14.5.2. Gaucher Disease

        14.5.3. Mucopolysaccharidosis

            14.5.3.1. MPS I

            14.5.3.2. MPS II (Hunter syndrome)

            14.5.3.3. MPS IVA (Morquio syndrome, type A)

            14.5.3.4. MPS VI (Maroteaux-Lamy syndrome)

            14.5.3.5. MPS VII (Sly syndrome)

        14.5.4. Pompe Disease

        14.5.5. Lysosomal acid lipase Deficiency

        14.5.6. Others

    14.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    14.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

        14.7.1. Oral

        14.7.2. Injectable

    14.8. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    14.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

        14.9.1. Hospital Pharmacies

        14.9.2. Specialty Treatment Pharmacies

        14.9.3. Retail Pharmacies

    14.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    14.11. Market Attractiveness Analysis

        14.11.1. By Country

        14.11.2. By Therapeutic Condition

        14.11.3. By Route of Administration

        14.11.4. By Distribution Channel

    14.12. Drivers and Restraints: Impact Analysis

    14.13. Key Market Participants – Intensity Mapping

15. Forecast Factors: Relevance and Impact

16. Market Structure Analysis

    16.1. Market Structure by Tier

    16.2. Market Share Analysis (2017) for Top 10 Players, By Region

17. Competition Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Profitability and Gross Margin Analysis By Competition

    17.4. Competitors Deep Dive

        17.4.1. Sanofi S.A. (Genzyme Corporation)

            17.4.1.1. Overview

            17.4.1.2. Product and Application Portfolio

            17.4.1.3. Production Footprint

            17.4.1.4. Sales Footprint

            17.4.1.5. Channel Footprint

            17.4.1.6. Strategy

                17.4.1.6.1. Marketing Strategy

                17.4.1.6.2. Product Strategy

                17.4.1.6.3. Channel Strategy

        17.4.2. Shire plc.

            17.4.2.1. Overview

            17.4.2.2. Product and Application Portfolio

            17.4.2.3. Production Footprint

            17.4.2.4. Sales Footprint

            17.4.2.5. Channel Footprint

            17.4.2.6. Strategy

                17.4.2.6.1. Marketing Strategy

                17.4.2.6.2. Product Strategy

                17.4.2.6.3. Channel Strategy

        17.4.3. Pfizer Inc.

            17.4.3.1. Overview

            17.4.3.2. Product and Application Portfolio

            17.4.3.3. Production Footprint

            17.4.3.4. Sales Footprint

            17.4.3.5. Channel Footprint

            17.4.3.6. Strategy

                17.4.3.6.1. Marketing Strategy

                17.4.3.6.2. Product Strategy

                17.4.3.6.3. Channel Strategy

        17.4.4. Alexion Pharmaceuticals, Inc.

            17.4.4.1. Overview

            17.4.4.2. Product and Application Portfolio

            17.4.4.3. Production Footprint

            17.4.4.4. Sales Footprint

            17.4.4.5. Channel Footprint

            17.4.4.6. Strategy

                17.4.4.6.1. Marketing Strategy

                17.4.4.6.2. Product Strategy

                17.4.4.6.3. Channel Strategy

        17.4.5. BioMarin Pharmaceutical Inc.

            17.4.5.1. Overview

            17.4.5.2. Product and Application Portfolio

            17.4.5.3. Production Footprint

            17.4.5.4. Sales Footprint

            17.4.5.5. Channel Footprint

            17.4.5.6. Strategy

                17.4.5.6.1. Marketing Strategy

                17.4.5.6.2. Product Strategy

                17.4.5.6.3. Channel Strategy

        17.4.6. Ultragenyx Pharmaceutical Inc.

            17.4.6.1. Overview

            17.4.6.2. Product and Application Portfolio

            17.4.6.3. Production Footprint

            17.4.6.4. Sales Footprint

            17.4.6.5. Channel Footprint

            17.4.6.6. Strategy

                17.4.6.6.1. Marketing Strategy

                17.4.6.6.2. Product Strategy

                17.4.6.6.3. Channel Strategy

        17.4.7. Johnson & Johnson Services, Inc.

            17.4.7.1. Overview

            17.4.7.2. Product and Application Portfolio

            17.4.7.3. Production Footprint

            17.4.7.4. Sales Footprint

            17.4.7.5. Channel Footprint

            17.4.7.6. Strategy

                17.4.7.6.1. Marketing Strategy

                17.4.7.6.2. Product Strategy

                17.4.7.6.3. Channel Strategy

        17.4.8. Allergan plc.

            17.4.8.1. Overview

            17.4.8.2. Product and Application Portfolio

            17.4.8.3. Production Footprint

            17.4.8.4. Sales Footprint

            17.4.8.5. Channel Footprint

            17.4.8.6. Strategy

                17.4.8.6.1. Marketing Strategy

                17.4.8.6.2. Product Strategy

                17.4.8.6.3. Channel Strategy

        17.4.9. Leadiant Biosciences, Inc.

            17.4.9.1. Overview

            17.4.9.2. Product and Application Portfolio

            17.4.9.3. Production Footprint

            17.4.9.4. Sales Footprint

            17.4.9.5. Channel Footprint

            17.4.9.6. Strategy

                17.4.9.6.1. Marketing Strategy

                17.4.9.6.2. Product Strategy

                17.4.9.6.3. Channel Strategy

18. Global Market Analysis 2013-2021 and Forecast 2022-2028 By Region

    18.1. Introduction / Key Findings

    18.2. Historical Market Size (US$ Mn) Analysis By Region

        18.2.1. North America

        18.2.2. Latin America

        18.2.3. Western Europe

        18.2.4. Eastern Europe

        18.2.5. Asia Pacific Excluding Japan And China

        18.2.6. China

        18.2.7. Japan

        18.2.8. Middle East and Africa

    18.3. Market Size (US$ Mn) Forecast By Region

    18.4. Market Attractiveness Analysis By Region

19. Global Market Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

    19.1. Introduction/Key Finding

    19.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Condition, 2013-2021

        19.2.1. Fabry Disease

        19.2.2. Gaucher Disease

        19.2.3. Mucopolysaccharidosis

            19.2.3.1. MPS I

            19.2.3.2. MPS II (Hunter syndrome)

            19.2.3.3. MPS IVA (Morquio syndrome, type A)

            19.2.3.4. MPS VI (Maroteaux-Lamy syndrome)

            19.2.3.5. MPS VII (Sly syndrome)

        19.2.4. Pompe Disease

        19.2.5. Lysosomal acid lipase Deficiency

        19.2.6. Others

    19.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2022-2028

    19.4. Market Attractiveness Analysis By Therapeutic Condition

20. Global Market Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

    20.1. Introduction/Key Finding

    20.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2021

        20.2.1. Oral

        20.2.2. Injectable

    20.3. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

    20.4. Market Attractiveness Analysis By Route of Administration

21. Global Market Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

    21.1. Introduction/Key Finding

    21.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2021

        21.2.1. Hospital Pharmacies

        21.2.2. Specialty Treatment Pharmacies

        21.2.3. Retail Pharmacies

    21.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    21.4. Market Attractiveness Analysis By Distribution Channel

22. Global Market Analysis 2013-2021 and Forecast 2022-2028

    22.1. Market Value Share Analysis By All Segment

    22.2. Y-o-Y Growth Analysis By All Segment

    22.3. Absolute $ Opportunity

23. Assumptions and Acronyms Used

24. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 03: Comparison of orphan drug regulation across the US, Europe, Japan, Korea, Taiwan and China, 2021

Table 04: Clinical Trials

Table 05: Clinical Trials

Table 06: Clinical Trials

Table 07: Clinical Trials

Table 08: Clinical Trials

Table 09: Clinical Trials

Table 10: Clinical Trials

Table 11: Clinical Trials

Table 12: Clinical Trials

Table 13: Clinical Trials

Table 14: Clinical Trials

Table 15: Clinical Trials

Table 16: Clinical Trials

Table 17: Clinical Trials

Table 18: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 19: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 20: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 21: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 22: North America Market Company Intensity Map

Table 23: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 24: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 25: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 26: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 27: Latin America Market Company Intensity Map

Table 28: Budget Impact Of Orphan Drugs In Western European Countries

Table 29: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 30: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 31: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 32: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 33: Western Europe Market Company Intensity Map

Table 34: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 35: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 36: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 37: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 38: Eastern Europe Market Company Intensity Map

Table 39: National Initiatives to support rare diseases and access to orphan drugs in Southeast Asia, 2016

Table 40: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 41: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 42: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 43: APECJ Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 44: APECJ Market Company Intensity Map

Table 45: Comparison of China orphan drug policies with other several major countries

Table 46: China Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 47: China Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 48: China Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 49: China Market Company Intensity Map

Table 50: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 51: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 52: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 53: Japan Market Company Intensity Map

Table 54: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 55: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 56: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 57: MEA Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 58: MEA Market Company Intensity Map

Table 59: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region

Table 60: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Therapeutic Condition

Table 61: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration

Table 62: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 01: Market Value Share By Region (2018)

Figure 02: Global Healthcare Expenditure in US$ Tn (2013-2021)

Figure 03: North America Market Value Share (2021A), By Country

Figure 04: North America Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 05: North America Market Size (US$ Mn) Analysis, 2013-2021

Figure 06: North America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 07: North America Market Y-o-Y growth (%) Comparison, By Country, 2022-2028

Figure 08: U.S. Market Size (US$ Mn) Analysis, 2013-2021

Figure 09: U.S. Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 10: Canada Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 11: Canada Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 12: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 13: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 14: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 15: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 16: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 17: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 18: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 19: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 20: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 21: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 22: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 23: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 24: North America Market Attractiveness Analysis, By Country

Figure 25: North America Market Attractiveness Analysis, By Therapeutic Condition

Figure 26: North America Market Attractiveness Analysis, By Route of Administration 

Figure 27: North America Market Attractiveness Analysis, By Distribution Channel 

Figure 28: Latin America Market Value Share (2021A), By Country

Figure 29: Latin America Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 30: Latin America Market Size (US$ Mn) Analysis, 2013-2021

Figure 31: Latin America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 32: Latin America Market Y-o-Y growth (%) Comparison, By Country, 2022-2028

Figure 33: Brazil Market Size (US$ Mn) Analysis, 2013-2021

Figure 34: Brazil Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 35: Mexico Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 36: Mexico Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 37: Rest of Latin America Market Size (US$ Mn) Analysis, 2013-2021

Figure 38: Rest of Latin America Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 39: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 40: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 41: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 42: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 43: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 44: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 45: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 46: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 47: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 48: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 49: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 50: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 51: Latin America Market Attractiveness Analysis, By Country

Figure 52: Latin America Market Attractiveness Analysis, By Therapeutic Condition

Figure 53: Latin America Market Attractiveness Analysis, By Route of Administration 

Figure 54: Latin America Market Attractiveness Analysis, By Distribution Channel 

Figure 55: Western Europe Market Value Share (2021A), By Country

Figure 56: Western Europe Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 57: Western Europe Market Size (US$ Mn) Analysis, 2013-2021

Figure 58: Western Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 59: Western Europe Market Y-o-Y growth (%) Comparison, By Country, 2022-2028

Figure 60: Germany Market Size (US$ Mn) Analysis, 2013-2021

Figure 61: Germany Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 62: U.K. Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 63: U.K. Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 64: France Market Size (US$ Mn) Analysis, 2013-2021

Figure 65: France Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 66: Italy Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 67: Italy Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 68: Spain Market Size (US$ Mn) Analysis, 2013-2021

Figure 69: Spain Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 70: Rest of Western Europe  Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 71: Rest of Western Europe  Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 72: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 73: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 74: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 75: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 76: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 77: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 78: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 79: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 80: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 81: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 82: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 83: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 84: Western Europe Market Attractiveness Analysis, By Country

Figure 85: Western Europe Market Attractiveness Analysis, By Therapeutic Condition

Figure 86: Western Europe Market Attractiveness Analysis, By Route of Administration 

Figure 87: Western Europe Market Attractiveness Analysis, By Distribution Channel 

Figure 88: Eastern Europe Market Value Share (2021A), By Country

Figure 89: Eastern Europe Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 90: Eastern Europe Market Size (US$ Mn) Analysis, 2013-2021

Figure 91: Eastern Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 92: Eastern Europe Market Y-o-Y growth (%) Comparison, By Country, 2022-2028

Figure 93: Russia Market Size (US$ Mn) Analysis, 2013-2021

Figure 94: Russia Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 95: Poland Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 96: Poland Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 97: Rest of Eastern Europe Market Size (US$ Mn) Analysis, 2013-2021

Figure 98: Rest of Eastern Europe Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 99: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 100: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 101: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 102: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 103: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 104: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 105: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 106: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 107: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 108: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 109: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 110: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 111: Eastern Europe Market Attractiveness Analysis, By Country

Figure 112: Eastern Europe Market Attractiveness Analysis, By Therapeutic Condition

Figure 113: Eastern Europe Market Attractiveness Analysis, By Route of Administration 

Figure 114: Eastern Europe Market Attractiveness Analysis, By Distribution Channel 

Figure 115: APECJ Market Value Share (2021A), By Country

Figure 116: APECJ Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 117: APECJ Market Size (US$ Mn) Analysis, 2013-2021

Figure 118: APECJ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 119: APECJ Market Y-o-Y growth (%) Comparison, By Country, 2022-2028

Figure 120: India Market Size (US$ Mn) Analysis, 2013-2021

Figure 121: India Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 122: Australia & NZ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 123: Australia & NZ Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 124: ASEAN Market Size (US$ Mn) Analysis, 2013-2021

Figure 125: ASEAN Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 126: Rest of APECJ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 127: Rest of APECJ Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 128: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 129: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 130: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 131: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 132: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 133: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 134: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 135: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 136: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 137: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 138: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 139: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 140: APECJ Market Attractiveness Analysis, By Country

Figure 141: APECJ Market Attractiveness Analysis, By Therapeutic Condition

Figure 142: APECJ Market Attractiveness Analysis, By Route of Administration 

Figure 143: APECJ Market Attractiveness Analysis, By Distribution Channel 

Figure 144: China Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 145: China Market Size (US$ Mn) Analysis, 2013-2021

Figure 146: China Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 147: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 148: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 149: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 150: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 151: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 152: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 153: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 154: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 155: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 156: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 157: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 158: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 159: China Market Attractiveness Analysis, By Therapeutic Condition

Figure 160: China Market Attractiveness Analysis, By Route of Administration 

Figure 161: China Market Attractiveness Analysis, By Distribution Channel 

Figure 162: Japan Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 163: Japan Market Size (US$ Mn) Analysis, 2013-2021

Figure 164: Japan Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 165: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 166: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 167: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 168: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 169: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 170: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 171: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 172: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 173: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 174: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 175: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 176: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 177: Japan Market Attractiveness Analysis, By Therapeutic Condition

Figure 178: Japan Market Attractiveness Analysis, By Route of Administration 

Figure 179: Japan Market Attractiveness Analysis, By Distribution Channel 

Figure 180: MEA Market Value Share (2021A), By Country

Figure 181: MEA Market Value Share (2021A), By Therapeutic Condition, Route of Administration and Distribution Channel

Figure 182: MEA Market Size (US$ Mn) Analysis, 2013-2021

Figure 183: MEA Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 184: MEA Market Y-o-Y growth (%) Comparison, By Country, 2022-2028

Figure 185: GCC Countries Market Size (US$ Mn) Analysis, 2013-2021

Figure 186: GCC Countries Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 187: South Africa & NZ Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 188: South Africa Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 189: Rest of MEA Market Size (US$ Mn) Analysis, 2013-2021

Figure 190: Rest of MEA Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 191: Fabry Disease Market Size (US$ Mn) Analysis, 2013-2021

Figure 192: Fabry Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 193: Gaucher Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 194: Gaucher Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 195: Mucopolysaccharidosis Market Size (US$ Mn) Analysis, 2013-2021

Figure 196: Mucopolysaccharidosis Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 197: Pompe Disease Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 198: Pompe Disease Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 199: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Analysis, 2013-2021

Figure 200: Lysosomal acid lipase Deficiency Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 201: Others Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 202: Others Market Size (US$ Mn) Forecast Analysis & Y-o-Y Growth (%), 2022-2028

Figure 203: MEA Market Attractiveness Analysis, By Country

Figure 204: MEA Market Attractiveness Analysis, By Therapeutic Condition

Figure 205: MEA Market Attractiveness Analysis, By Route of Administration 

Figure 206: MEA Market Attractiveness Analysis, By Distribution Channel 

Figure 207: Revenue Contribution by Tier Type (2021)

Figure 208: Global Market Share (%) Analysis

Figure 209: Global Market Attractiveness Analysis, By Region

Figure 210: Global Market Attractiveness Analysis, By Therapeutic Condition

Figure 211: Global Market Attractiveness Analysis, By Route of Administration 

Figure 212: Global Market Attractiveness Analysis, By Distribution Channel

Figure 213: Global Market Size and Y-o-Y, 2013-2021

Figure 214: Global Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 215: Global Market Absolute $ Opportunity, 2013–2028

Recommendations

Healthcare

Hypoparathyroidism Treatment Market

Published : May 2023

Healthcare

Enzyme Replacement Therapy Market

Published : October 2022

Healthcare

Mucopolysaccharidosis (MPS) Treatment Market

Published : July 2022

Explore Healthcare Insights

View Reports

Enzyme Replacement Therapy Market

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Cookie Policy